Serum Irisin Level In Leprosy Patients
1 other identifier
observational
58
1 country
1
Brief Summary
- Measurement of plasma irisin level in leprosy patients.
- Correlation of plasma irisin level between leprosy patients and healthy controls.
- Correlation of plasma irisin level in different leprosy types.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
May 10, 2024
CompletedFirst Posted
Study publicly available on registry
May 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2024
CompletedNovember 8, 2024
May 1, 2024
6 months
May 10, 2024
November 7, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
measurement of Serum Irisin
comparing the plasma irisin levels in leprosy patients with healthy Participants
24 hours
Study Arms (2)
Group A :(Leprosy Group)
About 29 patients newly affected with Leprosy and The plasma irisin level of the participants will be measured by enzyme-linked immunosorbent assay (ELISA).
Group B:(Control Group)
About 29 apparently healthy individuals and The plasma irisin level of the participants will be measured by enzyme-linked immunosorbent assay (ELISA).
Interventions
Measurement of plasma irisin level in leprosy patients.
Eligibility Criteria
Study will include patients with leprosy and healthy controls attending in the outpatient clinic of Dermatology, Venereology and Andrology, Aswan University Hospital, Aswan University.
You may qualify if:
- \- New cases of leprosy patients.
You may not qualify if:
- Old cases with leprosy.
- Patients with cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).
- Patients with polycystic ovary syndrome (PCOS), Nonalcoholic fatty liver disease (NAFLD) and metabolic bone diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aswan Universitylead
Study Sites (1)
Aswan University Hospital
Aswān, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Moustafa El Taieb, Professor
Department of Dermatology, Venereology and Andrology Faculty of Medicine, Aswan University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident at Dermatology, Venereology and Andrology
Study Record Dates
First Submitted
May 10, 2024
First Posted
May 16, 2024
Study Start
January 1, 2024
Primary Completion
July 1, 2024
Study Completion
July 15, 2024
Last Updated
November 8, 2024
Record last verified: 2024-05